These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2472430)

  • 21. A monoclonal antibody (NMC-VIII/10) to factor VIII light chain recognizing Glu1675-Glu1684 inhibits factor VIII binding to endogenous von Willebrand factor in human umbilical vein endothelial cells.
    Shima M; Yoshioka A; Nakajima M; Nakai H; Fukui H
    Br J Haematol; 1992 Aug; 81(4):533-8. PubMed ID: 1390241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Six amino acid residues in a 1200 Å2 interface mediate binding of factor VIII to an IgG4κ inhibitory antibody.
    Lin JC; Ettinger RA; Schuman JT; Zhang AH; Wamiq-Adhami M; Nguyen PC; Nakaya-Fletcher SM; Puranik K; Thompson AR; Pratt KP
    PLoS One; 2015; 10(1):e0116577. PubMed ID: 25615825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A monoclonal antibody to factor VIII inhibits von Willebrand factor binding and thrombin cleavage.
    Precup JW; Kline BC; Fass DN
    Blood; 1991 May; 77(9):1929-36. PubMed ID: 1902121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional domains on von Willebrand factor. Recognition of discrete tryptic fragments by monoclonal antibodies that inhibit interaction of von Willebrand factor with platelets and with collagen.
    Sixma JJ; Sakariassen KS; Stel HV; Houdijk WP; In der Maur DW; Hamer RJ; de Groot PG; van Mourik JA
    J Clin Invest; 1984 Sep; 74(3):736-44. PubMed ID: 6332119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes.
    Gilles JG; Lavend'homme R; Peerlinck K; Jacquemin MG; Hoylaerts M; Jorieux S; Mazurier C; Vermylen J; Saint-Remy JM
    Thromb Haemost; 1999 Jul; 82(1):40-5. PubMed ID: 10456452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epitope localization of anti-factor VIII monoclonal antibodies determined by recombinant peptides.
    Ware J; Toomey JR; Stafford DW
    Thromb Haemost; 1989 Apr; 61(2):225-9. PubMed ID: 2473538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoclonal antibodies against the human factor VIII von Willebrand molecule: characterization and potential for screening of von Willebrand patients.
    Avner P; Arnaud D; Sultan Y; Maisonneuve P; Jeanneau C
    Dev Biol Stand; 1984; 57():69-76. PubMed ID: 6084622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor.
    Shima M; Nakai H; Scandella D; Tanaka I; Sawamoto Y; Kamisue S; Morichika S; Murakami T; Yoshioka A
    Br J Haematol; 1995 Nov; 91(3):714-21. PubMed ID: 8555081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factor VIII inhibitors: von Willebrand factor makes a difference in vitro and in vivo.
    Shi Q; Kuether EL; Schroeder JA; Perry CL; Fahs SA; Cox Gill J; Montgomery RR
    J Thromb Haemost; 2012 Nov; 10(11):2328-37. PubMed ID: 22908929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain.
    Foster PA; Fulcher CA; Houghten RA; de Graaf Mahoney S; Zimmerman TS
    J Clin Invest; 1988 Jul; 82(1):123-8. PubMed ID: 2839543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site.
    Pratt KP; Qian J; Ellaban E; Okita DK; Diethelm-Okita BM; Conti-Fine B; Scott DW
    Thromb Haemost; 2004 Sep; 92(3):522-8. PubMed ID: 15351848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Localization of a factor VIII-inhibiting antibody epitope to a region between residues 338 and 362 of factor VIII heavy chain.
    Ware J; Toomey JR; Stafford DW
    Proc Natl Acad Sci U S A; 1988 May; 85(9):3165-9. PubMed ID: 2452445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope.
    Dimitrov JD; Roumenina LT; Plantier JL; Andre S; Saboulard D; Meslier Y; Planchais C; Jacquemin M; Saint-Remy JM; Atanasov BP; Kaveri SV; Lacroix-Desmazes S
    J Thromb Haemost; 2010 Jul; 8(7):1524-31. PubMed ID: 20374449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor.
    Vlot AJ; Koppelman SJ; van den Berg MH; Bouma BN; Sixma JJ
    Blood; 1995 Jun; 85(11):3150-7. PubMed ID: 7756647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A qualitative and quantitative analysis of von Willebrand factor contained in a very high-purity plasma-derived FVIII concentrate.
    Samor B; Michalski C; Brandin MP; Andre MH; Chtourou S; Tellier Z
    Vox Sang; 2012 Jul; 103(1):35-41. PubMed ID: 22239246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo.
    Tang L; Leong L; Sim D; Ho E; Gu JM; Schneider D; Feldman RI; Monteclaro F; Jiang H; Murphy JE
    Haemophilia; 2013 Jul; 19(4):539-45. PubMed ID: 23534820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-heavy-chain monoclonal antibodies directed to the acidic regions of the factor VIII molecule inhibit the binding of factor VIII to phospholipids and von Willebrand factor.
    Raut S; Villard S; Grailly S; Gilles JG; Granier C; Saint-Remy JM; Barrowcliffe TW
    Thromb Haemost; 2003 Sep; 90(3):385-97. PubMed ID: 12958606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between the binding sites for von Willebrand factor, phospholipid, and human factor VIII C2 inhibitor alloantibodies within the factor VIII C2 domain.
    Nogami K; Shima M; Giddings JC; Takeyama M; Tanaka I; Yoshioka A
    Int J Hematol; 2007 May; 85(4):317-22. PubMed ID: 17483075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterisation of a monoclonal antibody to von Willebrand factor as a potent inhibitor of ristocetin-mediated platelet interaction and platelet adhesion.
    Jorieux S; de Romeuf C; Samor B; Goudemand M; Mazurier C
    Thromb Haemost; 1987 Jun; 57(3):278-82. PubMed ID: 3116700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinetics of factor VIII-von Willebrand factor association.
    Vlot AJ; Koppelman SJ; Meijers JC; Dama C; van den Berg HM; Bouma BN; Sixma JJ; Willems GM
    Blood; 1996 Mar; 87(5):1809-16. PubMed ID: 8634427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.